Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103
Barbara Happl, Theresa Balber, Petra Heffeter, Christoph Denk, Joshua Welch, U. Köster, C Alliot, A.C. Bonraisin, Marie Brandt, Férid Haddad, Johannes H. Sterba, Wolfgang Kandioller, Markus Mitterhauser, Marcus Hacker, Bernhard K. Keppler, Thomas L. Mindt
Abstract
Radiolabeling of the chemotherapeutic agent BOLD-100 with ruthenium-103 enables animal experiments with lower amounts of injected drug. This leads to a relatively higher tumor uptake and promising tumor-to-background ratio for future imaging studies.
Topics & Concepts
RutheniumRuthenium redCombinatorial chemistryChemistryRadiochemistryOrganic chemistryCatalysisCalciumRadiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsNanoplatforms for cancer theranostics